Different viral agents are associated with an increased risk of more severe disease course and respiratory complications in immunocompromised patients.1–3 The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) responsible for a severe acute respiratory syndrome (SARS) represents a source of concern for the management of patients with inflammatory rheumatic diseases. Lombardy is the region in Northern Italy with the highest incidence of COVID-19 cases, with more than 33 000 confirmed patients and 1250 requiring admission to the intensive care unit within 1 month. Since the first reports of COVID-19 cases in Italy, we have circulated a survey with a 2-week follow-up contact to patients with chronic arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) followed up at our biological outpatient clinic in Pavia, Lombardy. The survey investigated the patients’ health conditions, the presence of contacts with subjects known to be affected by COVID-19 and management of …

中文翻译：

---

一系列接受免疫抑制靶向治疗的慢性关节炎患者的 COVID-19 临床过程

不同的病毒制剂与免疫功能低下患者发生更严重病程和呼吸系统并发症的风险增加有关。1-3 最近爆发的 2019 年严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 病 (COVID-19) 导致严重急性呼吸系统综合症 (SARS) 是炎症性风湿病患者管理的一个关注点。伦巴第是意大利北部 COVID-19 病例发病率最高的地区，有超过 33 000 名确诊患者和 1250 名需要在 1 个月内进入重症监护室的患者。自意大利首次报告 COVID-19 病例以来，我们已经分发了一项调查，对在我们位于帕维亚的生物门诊诊所接受生物改善疾病抗风湿药 (bDMARDs) 或靶向合成改善疾病抗风湿药物 (tsDMARDs) 治疗的慢性关节炎患者进行为期 2 周的随访，伦巴第。该调查调查了患者的健康状况、与已知受 COVID-19 影响的受试者的接触情况以及...